The I-neb adaptive aerosol delivery system enhances delivery of α1-antitrypsin with controlled inhalation

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue SUPPL. 1, 2010, Pages

  Geller, David E ^a   Kesser, Kenneth C ^a  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

1 antitrypsin; Aerosol devices; Breath control; Cystic fibrosis; I neb AAD system

Indexed keywords

ALPHA 1 ANTITRYPSIN;

AEROSOL; ARTICLE; BREATHING; CONTROLLED STUDY; DELIVERY TIME; DRUG DELIVERY SYSTEM; FILTER; HUMAN; IN VITRO STUDY; INHALATION; LASER DIFFRACTION; NEBULIZATION; NEBULIZER; NORMAL HUMAN; PARTICLE SIZE; SCINTIGRAPHY; SIMULATOR; TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ALPHA 1-ANTITRYPSIN; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RESPIRATORY MECHANICS; SERINE PROTEINASE INHIBITORS; TIME FACTORS;

EID: 77950626190     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0793     Document Type: Article

References (19)

1. Chmiel JF, KonstanMW: Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007;28:331-346.
2. Griese M, Kappler M, Gaggar A, Hartl D: Inhibition of proteases in cystic fibrosis lung disease. Eur Respir J 2008; 32:783-795.
3. Hubbard RC, Crystal RG: Strategies for aerosol therapy of alpha1-antitrypsin deficiency by the aerosol route. Lung Suppl. 1990;168:565-578.
4. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG: Aerosol a1-anti-trypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.
5. Berger M, Konstan MW, Hilliard JB: Aerosolized prolastin (a1-protease inhibitor) in CF. Pediatr Pulmonol. 1995;20:421.
6. Sawicki GS, Sellers DE, Robinson WM: High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cystic Fibros. 2009;8:91-96.
7. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Häussinger K: Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000;89:724-731.
8. Brand P, Meyer T, Häussermann S, Schulte M, Scheuch G, Bernhard T, Sommerauer B, Weber N, Griese M: Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 2005;18:45-54.
9. Nikander K, Denyer J: Adaptive aerosol delivery (AAD) technology. In: Rathbone MJ (ed). Modified Release Drug Delivery Technology, 2nd ed. Informa Healthcare USA, Inc., New York, NY; pp. 603-612, 2008.
10. Nikander K, Prince IR, Coughlin SR, Warren S, Taylor G: Mode of breathing-tidal or slow and deep-through the Ineb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA. Proceedings of Drug Delivery to the Lungs, Vol.17. Edinburgh, Scotland; pp. 206-209, 2006.
11. Laube BL, Jashnani R, Dalby RN, Zeitlin PL: Targeting aerosol deposition in patients with cystic fibrosis. Chest. 2000;118:1069-1076.
12. Bennett WD: Controlled inhalation of aerosolized therapeutics. Expert Opin Drug Deliv. 2005;2:763-767.
13. CSL Behring: Technical Operations memo: effect of nebulization on Zemaira specific activity. CSL Behring, King of Prussia, PA; 2007.
14. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS: Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol. 2006;41:177-183.
15. Brand P, Beckmann H, Enriquez MM, Meyer T, Müllinger B, Sommerer K, Weber N, Weuthen T, Scheuch G: Peripheral deposition of a1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003;22:263-267.
16. Köhler E, Sollich V, Schuster-Wonka R, Jorch G: Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients. J Aerosol Med 2005;18:386-395.
17. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D: a1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29:240-250.
18. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T: Lung deposition of inhaled a1-proteinase inhibitor in CF and a1-antitrypsin deficiency. Eur Respir J 2009;34:354-360.
19. Denyer J, Black A, Nikander K, Dyche T, Prince I: Domiciliary experience of the target inhalation mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med Pulm Drug Deliv. 2010;23(Suppl 1):S45-S54.